BridgeBio Stock Has Soared 29% in Just 3 Months. Here's Why Wall Street Thinks It Could Go Even Higher.

BridgeBio reported Q2 Attruby sales of $222M, more than tripling YoY from $71.5M, lifting total Q2 revenue to nearly $244M versus ~$111M a year earlier. The company also submitted NDAs for all three late-stage programs and said two were accepted for FDA review, while one (BBP-418) has a Nov. 27 PDUFA decision date for potential approval by year-end. Following the earnings update, Piper Sandler raised its price target and kept an “overweight” stance, reinforcing a broadly positive analyst outlook despite the company remaining unprofitable.

Analysis

The core setup is not “a good quarter,” it is a transition from discovery-mode biotech to a multi-asset commercial story. If Attruby keeps compounding over the next 1-2 quarters, the market should start capitalizing recurring revenue rather than discounting launch noise, which can compress the cost of capital and make the pipeline more valuable on a risk-adjusted basis. The key watch item is whether growth is driven by durable patient starts and persistence versus one-time inventory build; only the former supports a re-rate.

The second-order winner is any channel that expands ATTR-CM diagnosis velocity: cardiology practices, specialty pharmacies, and diagnostic workflows should see more volume if physician awareness keeps rising. The obvious loser is Pfizer’s incumbent ATTR franchise, but the bigger competitive effect may be on smaller rare-disease names that need launch execution to justify premium multiples; a strong bridge between a commercial asset and late-stage approvals raises the bar for everyone else in the gene/rare-disease complex. BBP-418 is the next catalyst that matters most because it converts the story from a one-drug launch into a platform with operating leverage.

Contrarian risk: the market may be over-anchored to the revenue runway and underpricing the possibility that launch momentum slows once the easiest patients are treated. If sequential growth decelerates, or if payer friction/gross-to-net expands, the stock can give back a large portion of its recent multiple expansion even before any pipeline readout. On the upside, a clean FDA decision on BBP-418 by late November could force model revisions and widen the valuation gap versus the broader biotech index over a 1-3 month horizon.

Key Decisions for Investors

• Long BBIO common into the Nov. 27 BBP-418 decision, but size it as a catalyst trade rather than a core hold; the upside is a re-rating on multi-asset optionality, while the downside is a 20-30% de-rate on a CRL or launch slowdown.
• For cleaner beta isolation, pair long BBIO / short XBI over the next 1-3 months: the idiosyncratic approval/launch path should outperform the basket if Attruby demand remains intact and the pipeline de-risks.
• If you want convexity, buy BBIO call spreads spanning the November PDUFA window; that captures upside from approval without paying full premium for the already-strong commercial momentum.
• Set a watch alert on sequential Attruby script growth and gross-to-net comments in the next earnings call; if sequential growth falls materially or payer pressure rises, reduce exposure because the stock is likely front-running a plateau.